Clinical Trial

Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.

Study acronym: SEQ
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a randomized, controlled clinical trial with a two-sided superiority hypothesis. The study evaluates whether a 12-week pre-treatment with semaglutide prior to ovarian stimulation improves the number of good-quality blastocysts in overweight and obese women undergoing in vitro fertilization (IVF), compared to no pre-treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-17; most recent amendment 2026-01-19.
Status change: Not Yet Recruiting → Recruiting 2026-01-19
Trial Details
NCT Number NCT07242534
Lead Sponsor Fundacion Dexeus
Conditions Infertility, Obesity
Enrollment 62 participants
Start Date 2026-01-19
Primary Completion 2027-02 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-01-21